Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

A novel polycyclic aromatic hydrocarbon derivative hole selective material (4PADNC) has been designed to optimize hole ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell ...

University of Hawaiʻi Cancer Center researchers found in laboratory and animal models that when breast cancers stop ...

Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...

Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a ...

A research team shows that environmentally relevant antibiotic levels can greatly accelerate the spread of antibiotic resistance genes.A research ...

Learn more about whether Legend Biotech Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Real-time index price for Nasdaq Industrial Index (INDS), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up for lost time. | Ipsen may be a recent entrant into the antibody-drug conjugate ...